According to Fortune Business Insights, the global cell therapy technologies market size was valued at USD 5.40 billion in 2025 and is projected to grow from USD 6.32 billion in 2026 to USD 22.73 billion by 2034, registering a CAGR of 17.34% during 2026–2034. The market is witnessing strong growth owing to the increasing number of cell therapy clinical trials, rising adoption of commercial CAR-T therapies, expansion of CDMO manufacturing capacity, and growing demand for closed, automated, and traceable manufacturing technologies.
Cell therapy technologies encompass a broad range of products, platforms, and services that support the research, development, manufacturing, testing, and commercialization of cell-based therapies. These technologies facilitate critical processes such as cell collection, isolation and selection, activation and engineering, expansion and culture, harvesting, fill-finish, analytical testing, and quality control.
The increasing development of CAR-T, TCR-T, TIL, NK-cell, stem cell, and iPSC-derived therapies is generating demand for advanced manufacturing systems and specialized laboratory technologies. Pharmaceutical and biotechnology companies are also investing in scalable and compliant infrastructure to transition cell therapy candidates from research and clinical development toward commercial manufacturing.
The growing utilization of regenerative medicine is one of the major factors supporting cell therapy technologies market growth. Regenerative therapies require sophisticated cell processing, cultivation, expansion, quality control, cryopreservation, and GMP manufacturing capabilities.
As more organizations develop stem cell, iPSC-derived, immune-cell, and tissue-repair therapies, demand is increasing for instruments, single-use assemblies, media, reagents, analytics systems, and CDMO services. The growing emphasis on maintaining cell viability, identity, potency, and safety is also encouraging the adoption of closed and scalable manufacturing systems.
For example, in August 2025, Sumitomo Pharma announced the completion of its CRAFT regenerative medicine and cell therapy manufacturing facility in Osaka, Japan, strengthening manufacturing capacity for regenerative medicine and cell therapy products.
Personalized healthcare is emerging as an important trend in the cell therapy technologies market. Autologous CAR-T and TIL therapies require patient-specific cells to be collected, modified or expanded, tested, and returned to the same patient.
This model is increasing demand for automated closed manufacturing systems, disposable assemblies, specialized media and reagents, quality control technologies, cryopreservation solutions, and digital chain-of-identity platforms. Technology providers are therefore focusing on automation, distributed manufacturing, and digital traceability to improve scalability and reduce manufacturing variability.
High manufacturing and therapy costs remain a major restraint for the market. Cell therapy production requires specialized facilities, highly skilled personnel, GMP-grade materials, single-use consumables, engineering technologies, quality control testing, cold-chain logistics, and stringent batch-release procedures.
The challenge is particularly significant for autologous therapies because individualized manufacturing runs can make production more expensive and difficult to scale. Consequently, companies are increasingly seeking automation and standardized manufacturing approaches to reduce costs and improve production efficiency.
Increasing investment in cell-based therapy development is creating significant opportunities for technology providers. Funding is supporting clinical programs, manufacturing facilities, automation platforms, quality control systems, and large-scale production infrastructure.
Investment in CAR-T, TCR-T, TIL, NK-cell, stem cell, and iPSC-derived therapies is consequently creating demand for cell processing systems, single-use technologies, media and reagents, analytical tools, software platforms, and CDMO services.
In September 2025, Cellares announced a USD 257 million Series D financing round led by BlackRock and Eclipse to support the industrialization of global cell therapy manufacturing.
Automation and closed-system manufacturing are becoming increasingly important as cell therapy developers seek to improve production consistency, reduce contamination risks, shorten manufacturing timelines, and support commercial-scale production.
The growing complexity of personalized therapies is encouraging manufacturers to integrate automated processing, digital monitoring, traceability, and advanced analytics into cell therapy workflows.
The expansion of contract development and manufacturing organizations is another important trend. Pharmaceutical and biotechnology companies are increasingly working with CDMOs to access specialized facilities, manufacturing expertise, and scalable production capabilities without making all infrastructure investments internally.
Digital platforms are gaining importance in cell therapy manufacturing because patient-specific products require accurate tracking throughout the production process. Chain-of-identity and chain-of-custody technologies help improve traceability and support regulatory compliance.
The market is segmented into:
Instruments & Automation Technologies
Single-use Assemblies
Media & Reagents
QC & Analytics Technologies
Software & Digital Platforms
Services
The media & reagents segment dominated the market in 2025, supported by recurring requirements across cell therapy development and manufacturing workflows. The segment is projected to account for 21.9% of the market in 2026.
Meanwhile, the software & digital platforms segment is expected to record a CAGR of 26.71% during the forecast period, supported by increasing demand for digital traceability and manufacturing management.
The market is categorized into:
Cell Collection
Cell Isolation & Selection
Cell Activation & Engineering
Cell Expansion & Culture
Harvest & Fill-Finish
Analytical Testing & Quality Control
The increasing complexity of engineered cell therapies is driving demand for advanced technologies across multiple workflow stages.
The market includes:
CAR-T Cell
TCR-T Cell
TIL
NK Cell
Stem Cell
iPSC-derived Cell
The CAR-T cell segment dominated the market in 2025 and is expected to account for 51.1% of the market in 2026. Its leading position is attributed to the commercial maturity of CAR-T therapies, the availability of approved products, expanding treatment-center networks, and increasing use in hematological cancers.
The market is divided into:
Research & Discovery
Process Development
Clinical Manufacturing
Commercial Manufacturing
The clinical manufacturing segment dominated in 2025 and is projected to hold a 26.6% share in 2026, driven by the growing number of cell therapy programs progressing through clinical trials and requiring GMP-compliant manufacturing.
The market is segmented into:
Pharmaceutical & Biotechnology Companies
CROs & CDMOs
Academic & Research Institutes
Others
The pharmaceutical & biotechnology companies segment led the market in 2025 and is expected to account for 45.8% of the market in 2026. Increasing in-house development and manufacturing investments, combined with partnerships with technology providers and CDMOs, support the segment's leading position.
North America held the leading position in the global market, accounting for 44.62% of the market in 2025. The regional market was valued at USD 2.41 billion in 2025. Strong commercial adoption of CAR-T therapies, extensive clinical trial activity, approved cellular and gene therapy products, and the presence of major technology suppliers and CDMOs are supporting regional growth.
The U.S. represents the largest market within North America and is projected to reach approximately USD 2.54 billion in 2026, representing around 40.1% of global revenue.
Europe is expected to experience steady expansion, with the regional market projected to register a 14.64% CAGR during the forecast period. Growing cell therapy research, manufacturing capabilities, and investments in advanced therapies are supporting regional development.
Asia Pacific is projected to reach approximately USD 1.41 billion in 2026. Increasing healthcare investment, expansion of regenerative medicine capabilities, and development of cell therapy manufacturing infrastructure are expected to support growth.
Japan's market is estimated to reach approximately USD 0.31 billion in 2026, representing roughly 4.8% of global revenue. The country is strengthening its position through investments in regenerative medicine and cell therapy manufacturing.
The global cell therapy technologies market is moderately consolidated, with major companies focusing on product innovation, automation, manufacturing capacity expansion, strategic collaborations, and service development.
Key players include:
Thermo Fisher Scientific Inc.
Danaher Corporation (Cytiva)
Sartorius AG
Lonza
Miltenyi Biotec
STEMCELL Technologies
Terumo Corporation
Catalent, Inc.
For example, in January 2025, Cytiva and Cellular Origins announced a collaboration to integrate Cytiva's automated Sefia platform with Cellular Origins' robotic Constellation platform, targeting scalable and cost-effective automated manufacturing of cell and gene therapies.
The cell therapy technologies market is expected to maintain strong growth through 2034 as pharmaceutical companies, biotechnology firms, research organizations, and CDMOs expand their capabilities for advanced cell-based therapies.
The increasing commercialization of CAR-T therapies, growth in regenerative medicine, rising investments in cell-based therapies, and demand for automated and closed manufacturing systems are expected to create new opportunities for technology suppliers. At the same time, high manufacturing costs and stringent regulatory requirements will encourage companies to prioritize scalable, standardized, digitally traceable, and cost-efficient production technologies.
The global cell therapy technologies market was valued at USD 5.40 billion in 2025 and is projected to reach USD 22.73 billion by 2034.
The market is expected to grow at a CAGR of 17.34% from 2026 to 2034.
By offering, the media & reagents segment dominated the market in 2025. By cell type, CAR-T cell therapy held the leading position, while clinical manufacturing dominated by scale of operation.
North America dominated the global market in 2025, accounting for a 44.62% market share.
Major companies operating in the market include Thermo Fisher Scientific Inc., Danaher Corporation (Cytiva), Sartorius AG, Lonza, Miltenyi Biotec, STEMCELL Technologies, Terumo Corporation, and Catalent, Inc.
Explore Japan’s Market Opportunities - Latest - Cell Therapy Technologies Market- Insights